A new neuromodulation method in chronic migraine; non-ınvasive pulsed radiofrequency, a single-blinded, randomised, controlled trial
© 2023. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland..
OBJECTIVE: Non-invasive pulsed radiofrequency (NipRF) therapy, a neuromodulation method for peripheral nerves, is a new treatment modality for pain. We aimed to show the changes in pain severity and frequency per month in chronic migraine with NipRF treatment.
METHODS: We treated patients diagnosed with chronic migraine according to the International Classification of Headache Disorders III beta diagnostic criteria. In half of the patients, we applied pulsed radiofrequency (pRF) treatment with transcutaneous electrodes to the greater occipital nerve (GON) trace. In the other half, we applied the GON block under ultrasound guidance. The Migraine Disability Assessment Scale (MIDAS) was administered to the participants, and those with scores > 2 were included in the study. Pain intensity and frequency were evaluated using the visual analog scale (VAS) and a headache diary completed before and 4 weeks after treatment.
RESULTS: When both groups were compared, the pre- and post-treatment VAS scores and headache frequencies were similar. Comparing the pre-treatment and post-treatment values within the groups, VAS scores and headache frequency decreased significantly after treatment in both groups (p < 0.001).
CONCLUSION: In this study, we observed that NipRF treatment is safe and effective for treating chronic migraine. Pain intensity and frequency decreased with NipRF treatment, similar to that in the GON block group.
CLINICAL TRIALS REGISTRATION NUMBER: NCT05499689, Date: 08/11/2022.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Irish journal of medical science - (2023) vom: 26. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Perdecioğlu, Gevher Rabia Genç [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic migraine |
|---|
| Anmerkungen: |
Date Revised 26.12.2023 published: Print-Electronic ClinicalTrials.gov: NCT05499689 Citation Status Publisher |
|---|
| doi: |
10.1007/s11845-023-03598-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366379348 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366379348 | ||
| 003 | DE-627 | ||
| 005 | 20231227141353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231227s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11845-023-03598-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1239.xml |
| 035 | |a (DE-627)NLM366379348 | ||
| 035 | |a (NLM)38147268 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Perdecioğlu, Gevher Rabia Genç |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A new neuromodulation method in chronic migraine; non-ınvasive pulsed radiofrequency, a single-blinded, randomised, controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05499689 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland. | ||
| 520 | |a OBJECTIVE: Non-invasive pulsed radiofrequency (NipRF) therapy, a neuromodulation method for peripheral nerves, is a new treatment modality for pain. We aimed to show the changes in pain severity and frequency per month in chronic migraine with NipRF treatment | ||
| 520 | |a METHODS: We treated patients diagnosed with chronic migraine according to the International Classification of Headache Disorders III beta diagnostic criteria. In half of the patients, we applied pulsed radiofrequency (pRF) treatment with transcutaneous electrodes to the greater occipital nerve (GON) trace. In the other half, we applied the GON block under ultrasound guidance. The Migraine Disability Assessment Scale (MIDAS) was administered to the participants, and those with scores > 2 were included in the study. Pain intensity and frequency were evaluated using the visual analog scale (VAS) and a headache diary completed before and 4 weeks after treatment | ||
| 520 | |a RESULTS: When both groups were compared, the pre- and post-treatment VAS scores and headache frequencies were similar. Comparing the pre-treatment and post-treatment values within the groups, VAS scores and headache frequency decreased significantly after treatment in both groups (p < 0.001) | ||
| 520 | |a CONCLUSION: In this study, we observed that NipRF treatment is safe and effective for treating chronic migraine. Pain intensity and frequency decreased with NipRF treatment, similar to that in the GON block group | ||
| 520 | |a CLINICAL TRIALS REGISTRATION NUMBER: NCT05499689, Date: 08/11/2022 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chronic migraine | |
| 650 | 4 | |a Greater occipital nerve block | |
| 650 | 4 | |a Migraine treatment | |
| 650 | 4 | |a Non-invasive pused radiofrequency | |
| 650 | 4 | |a Pulsed radiofrequency | |
| 700 | 1 | |a Ateş, Mehlika Panpallı |e verfasserin |4 aut | |
| 700 | 1 | |a Yürük, Damla |e verfasserin |4 aut | |
| 700 | 1 | |a Can, Ezgi |e verfasserin |4 aut | |
| 700 | 1 | |a Yıldız, Gökhan |e verfasserin |4 aut | |
| 700 | 1 | |a Akkaya, Ömer Taylan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Irish journal of medical science |d 1945 |g (2023) vom: 26. Dez. |w (DE-627)NLM000148970 |x 1863-4362 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:26 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11845-023-03598-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 26 |c 12 | ||